Fine-Tuning the Care of Patients With Moderate-to-Severe Crohn’s Disease Using Novel Targeted Therapies

Russell D. Cohen, MD
Uma Mahadevan, MD

MON MAY 20
Marriott Marquis Washington, DC
Marquis Ballroom Salons 1-4

6:00 - 6:30 PM Registration & Dinner
6:30 - 7:30 PM Symposium

To register, scan the QR code or go to: www.answersincme.com/IME-62534

ENGAGE IN DISCUSSION WITH THE EXPERTS

- Welcome and Introduction
- Exploring Unmet Needs in Moderate-to-Severe Crohn’s Disease (CD): The Rationale for Novel Targeted Therapies
- Acknowledging the Impact: The Latest Clinical Data for Approved JAK Inhibitors in Moderate-to-Severe CD
- Acknowledging the Impact: The Latest Clinical Data for Approved IL-23 Inhibitors in Moderate-to-Severe CD
- Individualizing Treatment Selection in Moderate-to-Severe CD: Key Factors to Consider
- Refining Personalized Care Using Novel Targeted Therapies in Moderate-to-Severe CD
- Questions and Take-Home Learnings

This program is not affiliated with Digestive Disease Week®.
This CME activity is jointly provided by Global Education Group and Answers in CME. There is no fee to participate in this activity.
This activity is supported by an educational grant from AbbVie Inc.
Please contact live@answersincme.com for more information.
2018-2024, Answers in CME